Loading clinical trials...

Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction | Clinical Trials | Clareo Health

COMPLETED

Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Adoption of Novel Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

NCT06671314•Novartis

View on ClinicalTrials.gov

Summary

This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims. The main goal of the study was to compare home-time in Medicare FFS patients with heart failure with mildly reduced or preserved ejection fraction discharged with sacubitril/valsartan versus those discharged without sacubitril/valsartan.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Hospitalized for heart failure from 01 January 2016 to 30 September 2021.
•Were discharged alive (any discharge disposition other than "Expired").
•Had Mildly reduced or preserved ejection fraction (41% to 60%).
•Had non-missing record of SAC/VAL use at discharge.
•Continuously enrolled in Medicare Part A \& B for the 12 months following the index HF hospitalization discharge date or until death.

Exclusion Criteria

•Patients who left against medical advice (AMA), were transferred to an acute care facility, or discharged to hospice care.
•Patients who had dialysis as an in-hospital procedure.
•Patients with a medical history of chronic dialysis.
•Patients with an in-hospital procedure of heart transplantation.
•Patients with a medical history of heart transplantation.
•Patients with an in-hospital procedure of left ventricular assist device.
•Patients with a medical history of left ventricular assist device.

Locations (1)

Novartis Pharmaceuticals

East Hanover, New Jersey, United States

Key Dates

Start Date

June 2, 2022

Primary Completion Date

October 31, 2022

Completion Date

October 31, 2022

Last Updated

November 4, 2024

Enrollment

42,494

ACTUAL participants

Conditions

Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction

Prospective Evaluation of AI-ECG for SHD Detection

NCT07057466

Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)Pulmonary Hypertension (Diagnosis)+2 more

View study

RECRUITING

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

NCT07093528

Heart Failure With Preserved Ejection FractionCoronary Microvascular Dysfunction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Inclusion Criteria

Exclusion Criteria

Prospective Evaluation of AI-ECG for SHD Detection

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

Assessment of CCM in HF With Higher Ejection Fraction